SC

SCYNEXIS

- NASDAQ:SCYX
Last Updated 2021-09-17

LinkedIn Profile

Access SCYNEXIS historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Sector Industry
nasdaq:scyx 70564 Sep 9th, 2021 12:00AM SCYNEXIS, Inc. 4.4K 76.00 Open Biotechnology Sep 9th, 2021 12:29PM Sep 9th, 2021 12:29PM SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant fungal infections. Our lead candidate, ibrexafungerp, is a broad-spectrum IV/oral antifungal agent representing a novel therapeutic class, that is in FDA review for the treatment of vaginal yeast infection also known as vulvovaginal candidiasis (VVC) and late-stage clinical development for multiple life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development Open 1 Evertrust Plaza Jersey City New Jersey US 07302 Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Sep 8th, 2021 12:00AM SCYNEXIS, Inc. 4.4K 76.00 Open Biotechnology Sep 8th, 2021 12:25PM Sep 8th, 2021 12:25PM SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant fungal infections. Our lead candidate, ibrexafungerp, is a broad-spectrum IV/oral antifungal agent representing a novel therapeutic class, that is in FDA review for the treatment of vaginal yeast infection also known as vulvovaginal candidiasis (VVC) and late-stage clinical development for multiple life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development Open 1 Evertrust Plaza Jersey City New Jersey US 07302 Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Sep 7th, 2021 12:00AM SCYNEXIS, Inc. 4.4K 76.00 Open Biotechnology Sep 7th, 2021 09:23AM Sep 7th, 2021 09:23AM SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant fungal infections. Our lead candidate, ibrexafungerp, is a broad-spectrum IV/oral antifungal agent representing a novel therapeutic class, that is in FDA review for the treatment of vaginal yeast infection also known as vulvovaginal candidiasis (VVC) and late-stage clinical development for multiple life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development Open 1 Evertrust Plaza Jersey City New Jersey US 07302 Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Sep 6th, 2021 12:00AM SCYNEXIS, Inc. 4.4K 76.00 Open Biotechnology Sep 5th, 2021 11:06PM Sep 6th, 2021 11:40AM SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant fungal infections. Our lead candidate, ibrexafungerp, is a broad-spectrum IV/oral antifungal agent representing a novel therapeutic class, that is in FDA review for the treatment of vaginal yeast infection also known as vulvovaginal candidiasis (VVC) and late-stage clinical development for multiple life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development Open 1 Evertrust Plaza Jersey City New Jersey US 07302 Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Sep 5th, 2021 12:00AM SCYNEXIS, Inc. 4.4K 76.00 Open Biotechnology Sep 5th, 2021 03:05PM Sep 5th, 2021 03:05PM SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant fungal infections. Our lead candidate, ibrexafungerp, is a broad-spectrum IV/oral antifungal agent representing a novel therapeutic class, that is in FDA review for the treatment of vaginal yeast infection also known as vulvovaginal candidiasis (VVC) and late-stage clinical development for multiple life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development Open 1 Evertrust Plaza Jersey City New Jersey US 07302 Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Sep 4th, 2021 12:00AM SCYNEXIS, Inc. 4.4K 76.00 Open Biotechnology Sep 3rd, 2021 11:06PM Sep 4th, 2021 01:45PM SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant fungal infections. Our lead candidate, ibrexafungerp, is a broad-spectrum IV/oral antifungal agent representing a novel therapeutic class, that is in FDA review for the treatment of vaginal yeast infection also known as vulvovaginal candidiasis (VVC) and late-stage clinical development for multiple life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development Open 1 Evertrust Plaza Jersey City New Jersey US 07302 Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Sep 3rd, 2021 12:00AM SCYNEXIS, Inc. 4.4K 76.00 Open Biotechnology Sep 3rd, 2021 12:50PM Sep 3rd, 2021 12:50PM SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant fungal infections. Our lead candidate, ibrexafungerp, is a broad-spectrum IV/oral antifungal agent representing a novel therapeutic class, that is in FDA review for the treatment of vaginal yeast infection also known as vulvovaginal candidiasis (VVC) and late-stage clinical development for multiple life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development Open 1 Evertrust Plaza Jersey City New Jersey US 07302 Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Sep 2nd, 2021 12:00AM SCYNEXIS, Inc. 4.4K 76.00 Open Biotechnology Sep 2nd, 2021 10:31AM Sep 2nd, 2021 10:31AM SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant fungal infections. Our lead candidate, ibrexafungerp, is a broad-spectrum IV/oral antifungal agent representing a novel therapeutic class, that is in FDA review for the treatment of vaginal yeast infection also known as vulvovaginal candidiasis (VVC) and late-stage clinical development for multiple life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development Open 1 Evertrust Plaza Jersey City New Jersey US 07302 Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Sep 1st, 2021 12:00AM SCYNEXIS, Inc. 4.4K 76.00 Open Biotechnology Sep 1st, 2021 10:07AM Sep 1st, 2021 10:07AM SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant fungal infections. Our lead candidate, ibrexafungerp, is a broad-spectrum IV/oral antifungal agent representing a novel therapeutic class, that is in FDA review for the treatment of vaginal yeast infection also known as vulvovaginal candidiasis (VVC) and late-stage clinical development for multiple life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development Open 1 Evertrust Plaza Jersey City New Jersey US 07302 Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Aug 31st, 2021 12:00AM SCYNEXIS, Inc. 4.4K 76.00 Open Biotechnology Aug 31st, 2021 10:01AM Aug 31st, 2021 10:01AM SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant fungal infections. Our lead candidate, ibrexafungerp, is a broad-spectrum IV/oral antifungal agent representing a novel therapeutic class, that is in FDA review for the treatment of vaginal yeast infection also known as vulvovaginal candidiasis (VVC) and late-stage clinical development for multiple life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development Open 1 Evertrust Plaza Jersey City New Jersey US 07302 Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.